Back Hepatitis B Hepatitis B Topics HBV Treatment

EASL 2014: Long-term Tenofovir Maintains Viral Suppression in People with Hepatitis B

Treatment with tenofovir (Viread) for 3 years remained effective in keeping hepatitis B virus (HBV) suppressed, normalizing liver inflammation, and potentially reducing liver disease progression, according to studies from Germany, France, and Spain presented at the 49thEASL International Liver Congress (EASL 2014) recently held in London.

alt

Read more:

EASL 2014: Adding Interferon to Antivirals May Improve Response for Hepatitis B Patients

Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in HBeAg positive chronic hepatitis B patients, as did added interferon after long-term nucleoside therapy, but adding interferon after a only short course of antivirals did not improve response, according to a set of studies presented at the 49th EASL International Liver Congress last week in London.

alt

Read more:

Updated Entecavir Label Expands Indication for Children with Hepatitis B

The U.S. Food and Drug Administration (FDA) last week approved new label information for entecavir (Baraclude), a nucleoside analog used to treat chronic hepatitis B virus (HBV) infection. The revised label expands the indication for pediatric use by children age 2 years and up.

alt

Read more:

EASL 2014: International Liver Congress Starts this Week in London

The European Association for the Study of the Liver's International Liver Congress (EASL 2014) takes place April 9-13 at the ExCel Centre in London. The annual conference is one of the key annual scientific meetings covering viral hepatitis and its complications. Also on Thursday, the World Health Organization (WHO) will release new global guidelines for hepatitis C.

alt

Read more:

Chronic Hepatitis B Treatment Guidelines

CHB Treatment Guideline Navigator

Mark Sulkowski from Johns Hopkins and Tram Tran from Cedars Sinai Medical Center help readers understand and make decisions using current guidelines for treatment of people with chronic hepatitis B. This continuing medical education (CME) activity is available for free to all, with credit available for physicians and nurses.

alt

Read more: